Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Receivables - Other (2024 - 2025)

Historic Receivables - Other for 10x Genomics (TXG) over the last 2 years, with Q4 2025 value amounting to $35.5 million.

  • 10x Genomics' Receivables - Other rose 575478.55% to $35.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $35.5 million, marking a year-over-year increase of 575478.55%. This contributed to the annual value of $35.5 million for FY2025, which is 575478.55% up from last year.
  • Latest data reveals that 10x Genomics reported Receivables - Other of $35.5 million as of Q4 2025, which was up 575478.55% from $52.8 million recorded in Q3 2025.
  • 10x Genomics' 5-year Receivables - Other high stood at $69.1 million for Q2 2025, and its period low was $606000.0 during Q4 2024.